Intermittent claudication as a predictor of outcome in patients with ischemic systolic heart failure: analysis of the Controlled Rosuvastatin Multinational Trial in Heart Failure trial (CORONA).

Publisher:
Oxford Journal
Publication Type:
Journal Article
Citation:
European Journal of Heart Failure, 2010, 12 (7), pp. 698 - 705
Issue Date:
2010-01
Full metadata record
Files in This Item:
Filename Description Size
Thumbnail2010005768OK.pdf125.12 kB
Adobe PDF
To examine the relationship between baseline intermittent claudication and outcomes in patients enrolled in the Controlled Rosuvastatin Multinational Trial in Heart Failure trial (CORONA). Intermittent claudication is an independent predictor of worse outcome in coronary heart disease, but its prognostic importance in heart failure (HF) is unknown. Patients aged .60 years with NYHA class II-IV, low ejection fraction HF of ischaemic aetiology were enrolled in CORONA. Rosuvastatin did not reduce the primary outcome or all-cause mortality.
Please use this identifier to cite or link to this item: